The Filing Desk

Sight Sciences

SGHT · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

SGHT · Last close · November 19, 2026
$10.62
Value Sight Sciences yourself

Sight Sciences' revenue fell 3.1% to $77 million in fiscal 2025. Its operating margin was −48.0%, up from −63.3% a year earlier. Free cash flow was −$30 million. The diluted share count rose 4.0%.

SIGHT SCIENCES, INC. Latest fiscal year ended December 31, 2025 10-K filed March 4, 2026 · 0001193125-26-091558 Updated
Revenue
$77M
3.1%
Operating margin
−48.0%
15.3 pts
Net income
−$38M
 
Free cash flow
−$30M
 
Return on equity
−50.7%
1.1 pts
Market cap
$585M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Sight Sciences does

Sight Sciences is a medical device company that makes tools for eye doctors to treat two eye conditions: glaucoma and dry eye disease. It sells to eyecare professionals, meaning ophthalmologists and optometrists, who use its devices in procedures. The products are used a limited number of times, so revenue depends on how often doctors use them.

It reports an Interventional Glaucoma line and an Interventional Dry Eye line. The glaucoma line has two products for minimally invasive glaucoma surgery: the OMNI Surgical System, a single-use handheld device that treats the eye's drainage pathway to lower eye pressure, and the SION Surgical Instrument, a bladeless tool that removes tissue in the drainage pathway. The dry eye line is TearCare, which uses a reusable controller and wearable eyelid pieces to heat and clear blocked oil glands. It sells OMNI and SION in the U.S. mainly through its own sales team.

The company says it competes with companies that have more financial and human resources, longer histories and established doctor relationships. It also says insurance coverage and payment for the procedures matter to its sales. As of December 31, 2025, it had 186 full-time employees.

Its biggest risks, as it describes them

  • It has a history of losses and depends heavily on sales of its few products.
  • Insurers may not cover or pay enough for procedures that use its glaucoma and dry eye products.
  • Eye doctors may not adopt its products, and they need training and patient selection to use them well.
  • It faces competitors with longer histories and more resources, and new treatments could emerge.
  • It relies on third-party manufacturers, some single-source suppliers, many of them outside the U.S.
From Sight Sciences's annual report on Form 10-K, filed March 4, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Sight Sciences lost money in fiscal 2025: a net loss of $38 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments26118513812092
Debt incl. finance leases3535354042
Net debt (negative means net cash)−226−150−103−80−50
Net debt to EBITDA—————
Debt to equity0.1x0.2x0.3x0.5x0.7x
Interest coverage−11.8x−18.8x−10.6x−10.8x−7.2x
Current ratio20.5x11.8x13.3x9.0x10.2x
Quick ratio20.3x11.4x12.7x8.6x9.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Sight Sciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $184,799 of Sight Sciences shares on the open market, and 6 insiders sold $2.3 million, $1.7 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 16, 2026Brenton TaylorEVP, Operations & R&DSold plan20,685$10.64$220,006Form 4
Jul 6, 2026Jeremy B. HaydenChief Legal OfficerSold plan12,733$5.51$70,159Form 4
Jul 6, 2026David BadawiChief Technology Officer, DirectorSold plan7,418$5.51$40,873Form 4
Jul 2, 2026Alison BauerleinChief Operating OfficerSold plan24,184$5.36$129,626Form 4
Jul 2, 2026James RodbergChief Financial OfficerSold plan6,902$5.36$36,995Form 4
Jul 1, 2026Paul BadawiPresident and CEO, Director, 10% ownerSold plan28,684$5.42$155,467Form 4
Jul 1, 2026Brenton TaylorEVP, Operations & R&DSold plan2,829$5.42$15,333Form 4
Jun 10, 2026Staffan EncrantzDirector, 10% ownerBought14,100$4.88$68,808Form 4
May 18, 2026Alison BauerleinChief Operating OfficerSold plan12,728$5.12$65,167Form 4
Apr 6, 2026Jeremy B. HaydenChief Legal OfficerSold plan13,761$3.55$48,852Form 4
Apr 6, 2026James RodbergChief Financial OfficerSold plan7,231$3.55$25,670Form 4
Apr 2, 2026Alison BauerleinChief Operating OfficerSold plan25,874$3.48$90,042Form 4
The latest 12 of 34 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 93 of 95 of 9
Rule of 40−45.5%−29.9%−41.8%
Altman Z''0.57−2.91−5.95
Accruals ratio−4.4%−18.8%−6.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rosePassPassPass
Revenue rose relative to assetsPassPassPass
F-score5 of 93 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Sight Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Sight SciencesFY25−3.1%−48.0%−38.7%——5
Pro DexFY2616.4%16.8%8.7%19.6%0.6x7Compare
TELA BioFY2515.8%−42.0%−35.7%−190.2%—4Compare
ElectromedFY2615.3%18.8%11.4%———Compare
AVITA MedicalFY2511.4%−59.4%−45.0%−354.1%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue284971818077
Revenue growth—77.1%45.7%13.6%−1.5%−3.1%
Gross profit184059696867
Research and development91623181815
Operating income−32−52−84−57−50−37
Net income−35−63−86−56−52−38
Diluted EPS (US$)−3.71−2.36−1.80−1.14−1.03−0.74
Diluted shares (millions)92748495052
Cash flow
Cash from operations−32−52−76−47−22−30
Capital expenditure111100
Free cash flow−33−53−77−48−23−30
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation0513151713
Balance sheet at fiscal year end
Cash and short-term investments6226118513812092
Debt incl. finance leases323535354042
Total assets73280213167143115
Total liabilities444853465551
Shareholders' equity−892321601208864
Margins and ratios
Gross margin66.7%82.4%82.7%85.3%85.5%86.2%
Operating margin−116.5%−105.2%−117.7%−70.7%−63.3%−48.0%
Net margin−125.5%−128.6%−120.9%−68.5%−64.5%−49.7%
Free cash flow margin−119.8%−109.0%−107.9%−59.2%−28.5%−38.7%
Rule of 40 (growth + FCF margin)—−31.9%−62.1%−45.5%−29.9%−41.8%
Return on capital——————
Return on equity—−87.9%−44.0%−39.6%−49.6%−50.7%
Return on assets—−35.7%−35.0%−29.3%−33.3%−29.8%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Sight Sciences' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Sight Sciences.